Themis Medicare per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹4.34₹0.12₹3.24₹4.73₹61.83
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹4.33₹0.12₹3.24₹4.72₹61.73
₹43.28₹43.28₹43.74₹41.03₹368.85
₹36.01₹37.16₹44.06₹41.48₹385.02
—−₹0.35₹3.77₹1.57₹17.49
−₹0.88−₹0.88₹2.10−₹0.43−₹13.75
—₹0.50₹0.50₹0.50₹5.00
9.29.29.29.20.9
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

THEMISMED₹98.44

Themis Medicare Limited

· Pharma & Health
₹ CrorePeersLINCOLNBAJAJHCARESIGACHIWANBURYAMRUTANJANAHCLANUHPHRMcap ₹907 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS61.834.733.240.124.34
Diluted EPS61.734.723.240.124.33
Book Value per Share368.8541.0343.7443.2843.28
Revenue per Share385.0241.4844.0637.1636.01
Cash Flow per Share17.491.573.77-0.35—
Free Cash Flow per Share-13.75-0.432.10-0.88-0.88
Dividends per Share5.000.500.500.50—
Shares Outstanding (cr)0.99.29.29.29.2
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.